Batiraxcept  (Synonyms: AVB-500; AVB-S6-500)

Batiraxcept (AVB-500; AVB-S6-500) is a selective, soluble AXL receptor and GAS6 inhibitor that targets the GAS6-AXL signaling axis. Batiraxcept is orally inactive and does not cross the blood-brain barrier. Batiraxcept competitively binds to GAS6 ((K_D <1 nM), preventing its interaction with the AXL receptor tyrosine kinase, thereby inhibiting downstream PI3K/AKT and MAPK signaling pathways, reducing tumor cell glycolysis, angiogenesis, and metastatic potential. Batiraxcept has demonstrated antitumor activity in preclinical models of endometrial, cholangiocarcinoma, and ovarian cancer by inhibiting tumor growth, invasion, and metastasis^[1][2][3].

Batiraxcept (2 μM; 24 h) inhibits the viability of chemoresistant endometrial cancer cells (ARK1, PUC198) and synergizes with 12.5 nM Paclitaxel (HY-B0015) to reduce glycolytic metabolites and pAKT signaling^[1].
Batiraxcept (100 μg/mL; 24 h) reduces the invasion and migration ability of cholangiocarcinoma cells (SNU1196, HUCCT1) in Matrigel invasion and scratch assays^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Batiraxcept (30 mg/kg; intraperitoneal injection; twice a week; 4 weeks) significantly inhibits tumor growth and metastasis, reduces tumor volume, and decreases metastatic nodules in a mouse endometrial cancer (ARK1 cell) xenograft model^[1].
Batiraxcept (50 mg/kg, 100 mg/kg; intraperitoneal injection; once every 2 days; 25 days) significantly reduces the dissemination of bile duct tumor cells in the peritoneal cavity in a mouse endometrial cancer (SNU1196 cell) xenograft model, and does not affect the body weight of immunodeficient mice^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

93.85 kDa

2268717-61-7

Liquid

Colorless to light yellow

[Batiraxcept]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  [AXL (AXL receptor tyrosine kinase, ARK, JTK11, Tyro7, UFO)]2-IGHG1 Fc (Fragment constant)

• [1]. Bruce SF, et al. GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis. Mol Cancer Ther. 2022 Aug 2;21(8):1348-1359.  [Content Brief]

  [2]. Kim J, et al. Targeting AXL Using the AVB-500 Soluble Receptor and through Genetic Knockdown Inhibits Bile Duct Cancer Growth and Metastasis. Cancers (Basel). 2023 Mar 21;15(6):1882.  [Content Brief]

  [3]. Toboni MD, et al. Inhibition of AXL and VEGF-A Has Improved Therapeutic Efficacy in Uterine Serous Cancer. Cancers (Basel). 2021 Nov 23;13(23):5877.  [Content Brief]